Phreesia (NYSE: PHR) Financial Analysis: Q2 Revenue Growth and Valuation Insights
- Mixed Fiscal Q2 Results: Phreesia (NYSE: PHR) reported EPS of $0.03, below the $0.09 consensus estimate used by some market-data providers. Revenue reached $129.46 million, representing 10.4% year-over-year growth.
- Improving Profitability: Quarterly net income increased to $1.9 million from $0.7 million, while adjusted EBITDA climbed to $32.9 million from $22.1 million.
- Solid Liquidity: Phreesia had a current ratio of approximately 1.76 and a debt-to-equity ratio of approximately 0.18 as of July 31, 2026. The company also reduced its long-term debt by $23.5 million during the quarter.
Phreesia (NYSE: PHR) is a healthcare technology company that provides a comprehensive patient intake and engagement platform. Its software helps healthcare organizations manage patient registration, insurance verification, clinical screening, scheduling, communications, and payment collection. These solutions are designed to improve the patient experience and make administrative workflows more efficient.
On September 2, 2026, Phreesia reported results for its fiscal second quarter of 2027, which ended July 31, 2026. The company generated GAAP diluted earnings per share of $0.03, compared with the $0.09 consensus estimate reported by MarketBeat and TradingView.
Consensus estimates can differ between financial-data providers. Zacks used an EPS estimate of approximately $0.11, resulting in a reported negative earnings surprise of 72.7%. Investors should therefore confirm which consensus source and accounting basis are being used when comparing reported earnings with expectations.
Phreesia’s revenue reached $129.46 million, up 10.4% from $117.26 million in the same quarter last year. Based on the $129.06 million estimate used by MarketBeat and TradingView, revenue exceeded expectations by approximately $0.40 million. However, Zacks used a slightly higher consensus and classified the result as a modest revenue miss.
The company nevertheless demonstrated meaningful operating improvement. Net income increased to $1.9 million from $0.7 million a year earlier, while adjusted EBITDA rose to $32.9 million from $22.1 million. Phreesia also generated $18.3 million in operating cash flow and $13.8 million in free cash flow.
Looking at valuation, Phreesia traded at a trailing Price-to-Earnings ratio of approximately 69 around the earnings announcement. The P/E ratio compares a company’s share price with its trailing earnings per share. Phreesia’s elevated multiple indicates that the stock’s valuation depends heavily on continued revenue growth and further profitability improvements. Because the share price and trailing earnings change over time, the ratio should be treated as a market snapshot.
Phreesia’s latest balance sheet showed $253.50 million in current assets and $143.84 million in current liabilities, producing a current ratio of approximately 1.76. This indicates that the company had about $1.76 in current assets for every dollar of current liabilities.
Total debt and finance-lease liabilities were approximately $66.45 million, compared with $371.85 million in stockholders’ equity, producing a debt-to-equity ratio of approximately 0.18. Phreesia also used its cash generation and available cash to reduce long-term debt by $23.5 million during the quarter.
Management maintained its fiscal 2027 outlook of $510 million to $520 million in revenue and $125 million to $135 million in adjusted EBITDA. Overall, the quarter showed continued revenue growth, expanding profitability, positive free cash flow, and lower debt, although the earnings miss and Phreesia’s elevated valuation leave the stock dependent on continued execution.
